Clinical efficacy of Shenkang Injection and its influence on C-reactive protein and interleukin-6 levels in patients with diabetic nephropathy

Objective To explore the clinical efficacy of Shenkang Injection and its influence on C-reactive protein( CRP) and interleukin-6( IL-6) levels in patients with diabetic nephropathy( DN). Methods A total of 120 patients with type 2 diabetes mellitus combined with DN admitted in our hospital from Jan. 2012 to Jan. 2014 were randomly divided into observation group and control group,60 cases for each. Control group was treated with high-quality protein diets and insulin to control blood glucose and pressure,on which basis observation group was added with intravenous injection of Shenkang Injection. Clinical efficacy,fasting blood glucose( FBG),Triglyceride( TG),total cholesterol( TC),serum creatinine( SCr),24 h urinary protein( 24 hUpro),CRP and IL-6 level changes before and after treatment in both groups were observed. Results Clinical efficacy was 90. 00%in observation group, evidently higher than 75. 00% in control group( P 0. 05).Above indexes were all improved obviously after treatment than treatment before( P 0. 0 5,P 0. 01) and were markedly lower in observation group than in control group( P 0. 01). Conclusion Shenkang Injection can effectively reduce IL-6 and CRP levels and decrease blood glucose and pressure,prolong disease progression and improve prognosis in DN patients.